ASP Isotopes Inc. · NASDAQ:ASPI
ASP Isotopes — Investor Presentation (April 2024)
41 slides from ASP Isotopes's investor presentation, April 2024
Slide 1: Corporate Overview
Corporate Overview April 2024 © ASP Isotopes Inc. 1
Slide 2: Forward Looking Statements
Forward Looking Statements Forward Looking Statements This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looki
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance ASPI's advanced technology leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Our goal is to use innovative technology to become an indispensable supplier of enriched isotopes to three multi-billion-dollar end markets. Medical Opportunity
Slide 4: Target Milestones - 2024
Target Milestones - 2024 Market Milestones Operational Milestones • Secure at least 2 additional supply agreements • Start commercial production of isotopes at our for isotopes critical for new technologies and enrichment facilities in South Africa. – Mid-2024 healthcare. • Start constructing a firs
Slide 5: What is an Isotope?
What is an Isotope? Isotopes are like identical twins or triplets: very similar in most aspects, except for a few subtle differences. • Isotopes are two or more atoms of the same chemical element with the same number of protons and electrons but slightly different numbers of neutrons. • Isotopes are
Slide 6: Isotope Supply Chain
Isotope Supply Chain Isotopes have one of the most severely compromised supply chains of 15% any material in the world and are critical to many end markets including nuclear medicine, energy, food and water: • Global isotope production is dominated by Russia (85%) 85% with the remainder produced in
Slide 7: Our Technologies
Our Technologies Aerodynamic Separation Process (ASP) Quantum Enrichment (QE) The Aerodynamic Separation Process utilizes gaseous Quantum enrichment technology employs precisely tuned diffusion via a stationary wall centrifuge paired with lasers and quantum mechanical principles to efficiently propr
Slide 8: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights Cost-Effective Isotope enrichment facilities using our technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. Modular, Scalable Design The plants can be small in footprint and modular in design, allowing
Slide 9: The Opportunity in Nuclear Medicine
The Opportunity in Nuclear Medicine © ASP Isotopes Inc. 9
Slide 10: The Opportunity in Nuclear Medicine
The Opportunity in Nuclear Medicine • The global medical isotope market generated $5.1 billion in 2022 and is anticipated to generate $11.4 billion by 2032.2 • Benefitting from increased regulatory approvals and R&D spend in the radiopharmaceuticals sector. • Pipeline advancements have created multi
Slide 11: Nuclear Medicine: Isotopes of Interest
Nuclear Medicine: Isotopes of Interest End Market Carbon-Dating & Pharmacokinetic 14C Tracing 99Tc SPECT Scan Imaging 68Ga PET Scan Imaging 67Cu 64Cu Oncology Treatment Non-Hodgkin lymphoma, Prostate Cancer, NETs 177Lu Neuroendocrine Tumors NETs Short half-life Stable Isotopes Radioisotopes © ASP Is
Slide 12: Isotope End Markets: Molybdenum-100
Isotope End Markets: Molybdenum-100 (100Mo) Current Isotope Conversion Process 99Mo 99Tc Single-photon emission 99Tc Half-Life: 66 Hours Half-Life: 6 Hours computed tomography (SPECT) Technetium-99 ASP Isotope Conversion Process Global Market Size3 99Tc Global Market Size3 100Mo 99Tc $4.61B $4.17B S
Slide 13: Isotope End Markets: Ytterbium-176
Isotope End Markets: Ytterbium-176 (176Yb) Consensus Forecasts (US$) for Pluvicto Radiopharmaceutical Theranostics 176Yb Global Market Size Ytterbium-176 $1.8bn 176Yb Global Market Size The radiopharmaceutical theranostics market is expected to be worth $3.43bn by 2028, growing at a $100m CAGR of 11
Slide 14: Isotope End Markets: Zinc-68
Isotope End Markets: Zinc-68 (68Zn) ~75% of 68Ga market Positron emission tomography Structural demand not likely to be Supply Gap (PET) ~15x Increase in satisfied by Gallium-68 Market Demand generators Global Market Size4 68Ga Global Market Size5 $1.15B $127M 100% Supplied by Generators ~25% Suppli
Slide 15: Isotope End Markets: Carbon-14
Isotope End Markets: Carbon-14 (14C) Historically, Russia has been the sole supplier of Carbon-14. Availability of the Medical tracing isotope since the start of 2022 has been intermittent and unreliable. Now customers Global Market Size $10m p/a are seeking alternative suppliers to meet their deman
Slide 16: Medical Isotopes – Timelines
Medical Isotopes – Timelines © ASP Isotopes Inc. 16
Slide 17: The Opportunity in Semiconductors
The Opportunity in Semiconductors © ASP Isotopes Inc. 17
Slide 18: The Opportunity in Semiconductors: Materials
The Opportunity in Semiconductors: Materials ASPI can establish itself as an indispensable part of the semiconductor supply chain. Our Silicon-28 enrichment plant in South Africa • Using our proprietary technology and increasing capacity our goal is to become the world’s leading supplier of enriched
Slide 19: Silicon-28: Technological Breakthrough
Silicon-28: Technological Breakthrough • Electronics are relatively affordable because Silicon is cheap and abundant. But, although naturally occurring Silicon is a For many decades, researchers theorized that chips good conductor of electricity, it is not a good conductor of heat made of pure Silic
Slide 20: Plan for Growth: Scaling into New Isotopes
Plan for Growth: Scaling into New Isotopes Iceland is a desirable location for ASPI’s expansion for several reasons. Here we expect to produce multiple enriched Isotopes supported by long-term contracts with significant partners. Planned isotopes include Silicon-28, Germanium-72 & 74, Xenon-129, Deu
Slide 21: The Opportunity in Nuclear Energy
The Opportunity in Nuclear Energy © ASP Isotopes Inc. 21
Slide 22: The Problem is Well-Known...Solving it is not as Straightforward
The Problem is Well-Known...Solving it is not as Straightforward Global electricity production needs to double by 2050 and Net Zero targets have been set across the world. • During COP28, 24 countries backed a Ministerial Declaration calling for the tripling of global nuclear energy capacity by 2050
Slide 23: SMR (Small Modular Reactors): Next Wave in Nuclear Energy
SMR (Small Modular Reactors): Next Wave in Nuclear Energy The world is moving to a new type of nuclear reactor: SMR TerraPower’s Natrium The US DOE has already committed billions of dollars to Advanced Reactor Design Program (ARDP) to facilitate and accelerate development of advanced reactors. • Mod
Slide 24: HALEU Supply: A Growing Concern for SMRs
HALEU Supply: A Growing Concern for SMRs • Current commercial light water reactors use low-enriched uranium Annual US Demand Growth for HALEU (LEU) fuel which has less than 5% 235U content. 700 • Many SMRs and advanced reactors will require High Assay Low 600 Enriched Uranium (HALEU) with 235U enric
Slide 25: Our Technology: What is Quantum Enrichment (QE)?
Our Technology: What is Quantum Enrichment (QE)? • Isotopes of every element have unique spectroscopic “signatures” defined by the electromagnetic radiation or “light” absorbed by their atoms from electron transitions. • QE separates two isotopes by taking advantage of the slight differences in the
Slide 26: Comparing and Contrasting Enrichment Methods
Comparing and Contrasting Enrichment Methods Atomic Vapor Laser Gaseous Diffusion Centrifugation Isotope Separation Silex Systems Quantum Leap Energy (AVLIS) Cost High capital cost Capital 1/10 of Diffusion Low Capital, small size Low Capital, small size Low Capital, small size Adiabatic expansion n
Slide 27: Quantum Enrichment: Real World Experience
Quantum Enrichment: Real World Experience Laser Enrichment of Lithium 6 Heavy isotope >90% Our team have used lasers to enrich many different metals • Uranium Light isotope <10% • Lithium (the only isotopes where results have been published) • Zirconium • Zinc Light isotope >90% The separation proce
Slide 28: Nuclear Fuel: Supply Chain and Prices
Nuclear Fuel: Supply Chain and Prices • Uranium supply has been in a state of sustained deficit since 2018, which is widening due to years of underinvestment in uranium assets, resulting in production issues from the world's largest suppliers. • Meanwhile, demand for front-end nuclear fuel (U3O8, UF
Slide 29: Implications for HALEU
Implications for HALEU • If available (currently there is no Western Supplier of HALEU), HALEU would likely cost >$18,000 per Kg. • Many SMR companies based their business plans assuming HALEU <$10,000 per Kg. We believe Quantum Enrichment may allow for HALEU production at significantly lower prices
Slide 30: Potential to Close the Loop on Nuclear Waste
Potential to Close the Loop on Nuclear Waste Depleted tails from other uranium enrichers produce nuclear waste. The management of this waste is becoming a problem. We believe that our technology can process this waste into HALEU - Potentially providing a solution to this growing environmental proble
Slide 31: Investment Overview
Investment Overview Leverage the following… To capitalize on three multi-billion- dollar opportunities… Proven Proprietary Technology ASPI's advanced technologies leverage 20 years of R&D history to enrich isotopes in varying levels of atomic mass, allowing it to meet the growing demand in the Nucle
Slide 32: Appendix
Appendix © ASP Isotopes Inc. 32
Slide 33: Current Group Structure
Current Group Structure • Most customers contract through ASPI Guernsey ASP Isotopes Inc • Quantum Leap Energy (QLE) will likely be spun out as a separate • Intellectual Property largely owned by ASPI (UK) Delaware (US) company with its own management team and independent board NASDAQ (ASPI) of dire
Slide 34: Company History
Company History Nov 2023 • ASP acquires 51% of the outstanding capital stock of PET Labs (SA) • ASPI Commits to add two additional cyclotrons into October 2021 South Africa • ASP Isotopes wins competitive auction June 2023 for Klydon Large-scale Plant July 2022 March 2023 April 2024 • Raised an addi
Slide 35: One of the Most Experienced Laser Groups in the World
One of the Most Experienced Laser Groups in the World Our team has designed and constructed lasers for the following customers… © ASP Isotopes Inc. 35
Slide 36: ASPI: Employees Demographics
ASPI: Employees Demographics We now have over 70 employees... 19% of employees have PhDs 41% of employees have advanced degrees or higher Employees By Nationality Employees By Role Radioisotope Engineering, Non South African Production and 15% 3% distribution, 23% Adminstration Plant 12% constructio
Slide 37: ASP Isotopes: Leadership Team
ASP Isotopes: Leadership Team PAUL MANN HENDRIK STRYDOM, PhD GERDUS KEMP, MD, PhD Chairman, and CEO Director, Chief Technology Officer Medical Director, CEO PET Labs • Co-founded ASP Isotopes in • Co-developer of “Aerodynamic • CEO Pet-Labs, a South African September 2021 Separation Process” (ASP) a
Slide 38: ASP Isotopes: Senior Management
ASP Isotopes: Senior Management Xandra Van Heerden, PhD Heino Van Wyk Ben Swanepoel Robert Ainscow Head of R&D Head of Engineering Head of Chemistry Chief Operating Officer and Chief Financial Officer ▪ Head of Research & ▪ Process engineer with ▪ Head of Chemistry at ASP. Development at ASP. design
Slide 39: ASP Isotopes: Scientific Advisors
ASP Isotopes: Scientific Advisors PROF EINAR RONANDER, PhD Chief Scientific Advisor ▪ Globally recognized as a leading scientist in the field of isotope separation for medical and industrial applications ▪ Pioneered the Molecular Laser Isotope Separation (MLIS) and the Atomic Vapour Laser Isotope Se
Slide 40: ASP Isotopes: Non-Executive Directors
ASP Isotopes: Non-Executive Directors PROF MIKE GORLEY, PhD TODD WIDER, MD DUNCAN MOORE, PhD ROB RYAN Director Director Director Director ▪ Director of Fusion ▪ Executive Chairman and ▪ Partner at East West ▪ 30+ years private investor Technology at the U.K. Chief Medical Officer, Capital Partners,
Slide 41: Data Sources
Data Sources 1. Meeting Isotope Needs and Capturing Opportunities for the Future: the 2015 Long Range Plan for the DOE Isotope Program https://www.osti.gov/servlets/purl/1298983 2. Medical Isotope Market to Reach $11.4 Billion Globally By 2032 | CAGR:8.8% : Allied Market Research Medical Isotope Mar